11 November 2021Big PharmaAlex Baldwin

PTAB grants IPR of Regeneron Eylea patents

The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pressure-reducing eye drop patents in dispute

5 July 2022 Licensing partners aim to prevent the introduction of a proposed eye drop generic treatment before the expiration of four patents.

article

Regeneron convinces PTAB to review Novartis syringe patent

28 October 2021 The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron.

Big Pharma

Regeneron asks court to dismiss COVID-19 tech patent suit

24 August 2021 Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

PTAB grants IPR of Regeneron Eylea patents

More on this story

Editor's picks

Editor's picks

More features